Experimental compound counters diabetic complications

An experimental compound reduced complications of type 1 and type 2 diabetes in mice – not by lowering blood sugar – but by countering its consequences: cell death, inflammation, and organ damage.

Published online in Science Translational Medicine on November 24, the study reported that a new class of compounds blocked the ability of a protein called RAGE to pass on inflammatory signals that injure the heart and kidneys in diabetes, and that slow the healing of diabetic wounds.

The results revolve around the body’s immune system, which recognizes and destroys invading bacteria and viruses. This system’s activation causes inflammation, responses like swelling and pain that result from the homing in by immune cells into sites of infection or injury. Many diseases – including diabetes – include misplaced inflammation that damages tissues.

Experiments in human cells and mouse models found that the lead study compound, RAGE229, significantly reduced short- and long-term complications of diabetes.

“Our results establish the molecular backbone of RAGE229 as the foundation for a new approach that targets intracellular RAGE actions to counter diabetic tissue damage,” says lead study author Ann Marie Schmidt, MD, the Dr. Iven Young Professor of Endocrinology at NYU Grossman School of Medicine. “With further refinements, RAGE229 and its descendants have great potential to fill gaps in treatment, including that most current drugs work only against type 2 diabetes.”

Picking a Lead

Most narratives of diabetes say that diet and age (Type 2) or genetic differences (Type 1) reduce action or production of the hormone insulin, which keeps blood sugar levels in check after meals supply the body with energy. While high blood sugar causes inflammatory damage, past work has also established that mechanisms occurring later in, and common to, both types of diabetes could be targeted separately by novel drug candidates.

In particular, high blood sugar generates greater numbers of charged particles that tear apart cell components like DNA. This kills cells, which fall apart and spill their contents, including damage-associated molecular patterns or DAMPS. Such “danger molecules” inform the body that a tissue is under stress, in some cases by activating RAGE, say the authors.  When a DAMP docks into RAGE on a cell’s outer surface, it changes the receptor’s shape to pass messages into the cell’s inner compartment, the cytoplasm. Schmidt and colleagues had shown previously that the RAGE cytoplasmic “tail” (ctRAGE) interacts with a protein called DIAPH1 to pass on such messages, which ultimately activate inflammatory genes.

The current research team screened through a library of 59,000 compounds to ultimately develop RAGE229, the candidate that best interfered with the DIAPH1:ctRAGE interaction. Using a test that triggers inflammation in mice as measured by swelling in their paws, the team showed that those treated with RAGE229 had a significantly lower inflammation score of 2.5 (on a 1-5 scale) versus a score of 3.3 in mice given an inert solvent, also called a vehicle, for comparison.

Other experiments reflected the increased risk for heart attack in patients with diabetes, created in part by higher inflammation levels. In male mice with type-1-like diabetes and a temporary blockage of a coronary artery, simulating a heart attack, the researchers found that the amount of heart muscle that died (infarct volume) downstream of a blockage was 28 percent in RAGE229-treated mice, versus 38 percent in mice treated with vehicle.

The team next incorporated the RAGE229 molecule into mouse chow because dietary intake could better measure its ability to reverse long-term complications like diabetic wounds. High blood sugar and related inflammation have been shown to interfere with cells that create scar tissue to close wounds. The researchers found that the percent of wound closure after 21 days was 90 percent in male type 2 diabetic mice treated with RAGE229, compared to 65 percent in those treated with vehicle. Both male and female mice treated with RAGE229 also had significantly better healing than vehicle-treated mice at the microscopic level (histological evidence).

The research team also found that male and female type 1-like or type-2-like diabetic mice fed RAGE229 chow had significantly less kidney damage than mice fed control chow by several measures, including reduced inflammation-driven mesangial sclerosis – protein build-up that reduces the organs’ capacity to properly filter wastes from the bloodstream.

“The RAGE229 used in the our study will not the be version recommended should it move forward into human clinical trials,” says Schmidt. “We continue to aggressively synthesize and test new compounds and chemically modifications RAGE229. These new molecules promise to yield a final drug candidate with optimal potency in the foreseeable future.”

***

Along with Schmidt and first study author Michaele Manigrasso, authors from the Diabetes Research Program, Division of Endocrinology, Diabetes and Metabolism were Nosirudeen Quadri, Lander Egaña-Gorroño, Laura Frye, and Ravichandran Ramasamy; along with Piul Rabbani of the Hansjörg Wyss Department of Plastic Surgery; Boyan Zhou and Huilin Li in the departments of Population Health and Environmental Medicine; all at NYU Langone Health. Also authors were Lisa Ramirez, Sergey Reverdatto, Stephen Dansereau, Jinhong Pan, and co-senior author Alexander Shekhtman of the Department of Chemistry, The State University of New York at Albany; Vivette D’Agati in the Department of Pathology at Columbia University Irving Medical Center, and Robert DeVita of RJD Medicinal Chemistry and Drug Discovery Consulting LLC, in Westfield, N.J.

The study was funded by U.S. Public Health Service grants 1R24DK103032, 1R01DK122456-01A1, P01HL146367, and 1P01HL131481; U.S. Department of Defense awards W81XWH-17-1-0201 and W81XWH-17-1-0202; and NYU Cancer Institute cancer center support grant 5P30CA016087-31.

Journal: Science Translational Medicine
DOI: 10.1126
Method of Research: Experimental study
Subject of Research: Animals
Article Title: Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice
Article Publication Date: 24-Nov-2021
COI Statement: Drs. Manigrasso, Ramasamy, and Schmidt have patents and patent applications through NYU Grossman School of Medicine that have been submitted/published and that are directly related to the work detailed in this manuscript. These include the following: (i) Patent Number 10,729,695 (United States), Amino, amido, and heterocyclic compounds as modulators of RAGE activity and uses thereof; (ii) patent number 10,265,320 (United States), Amino, amido, and heterocyclic compounds as modulators of RAGE activity and uses thtereof; (iii) application number 14851038.1 (pending, Europe), Amino, amido, and heterocyclic compounds as modulators of RAGE activity and uses thereof; (iv) application number 16/094,720 (pending but the application has been allowed, United States), Quinoline compounds as modulators or RAGE activity and uses thereof; (v) application number 17786436.0 (pending, Europe), Quinoline compounds as modulators or RAGE activity and uses thereof; and (vi) application number PCT/US2020/044926 (pending, United States), Indole compounds as modulators of RAGE activity and uses thereof. Dr. Schmidt is an unpaid consultant for Peles Therapeutics.

Media Contact

Gregory Williams
NYU Langone Health / NYU Grossman School of Medicine
gregory.williams@nyumc.org
Office: 212-404-3533

www.nyumc.org